Breaking News

PPD Appoints Biomarker Lab Director

By Kristin Brooks | February 26, 2014

Bennett brings 25 years of lab and biomarker experience

Patrick Bennett has been appointed executive director of lab operations for PPD’s new biomarker services division of its bioanalytical lab. PPD’s bioanalytical labs facilities in Richmond, VA, and Middleton, WI, provide customized biomarker measurement, comprehensive assay development, method development, validation, transfer and sample analysis, validated methods to quantitatively measure all types of compounds, chromatography, immunochemistry, and metabolite identification.
Mr. Bennett joins the company from Thermo Fisher Scientific, where he served as global strategic marketing director for pharma/biopharma life sciences mass spectrometry, and led efforts to develop, manage and implement marketing strategies. Prior to that, he served as vice president of business development and marketing and executive lab director at Tandem Labs, where he managed scientific and regulatory leadership activities.
“Patrick brings more than 25 years of experience in laboratories and biomarker services,” said David Johnston, Ph.D., PPD’s executive vice president of global laboratory services. “At PPD, our bioanalytical labs provide state-of-the-art facilities and instrumentation, scientific expertise, experienced regulatory staff and capabilities in a wide variety of technologies and methods. Patrick will lead and drive strategy for comprehensive biomarker development and testing from discovery through approval of predictive medicine biomarkers for both large and small molecule therapeutics.”

Related Compliance:

  • Patheon Furthers Expansion Strategy

    Kristin Brooks, Contract Pharma||January 9, 2017
    Patrick Glaser of Patheon discusses expanded manufacturing capacity, capabilities, and future plans

  • API Sourcing Trends

    Kristin Brooks, Contract Pharma||April 11, 2016
    Drug product complexities, quality and regulatory hurdles drive market shift

  • Setting a Precedent for Biosimilars in the U.S.

    Setting a Precedent for Biosimilars in the U.S.

    Kristin Brooks, Contract Pharma||May 19, 2015
    Niall Dinwoodie of Charles River discusses several key industry issues on biosimilars and addresses some of the development and regulatory hurdles that remain

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent

  • Biopharma CMO Market Trends

    Biopharma CMO Market Trends

    Tim Wright, Editor||June 2, 2016
    Continued strong growth in biopharma industry is being driven by biosimilars

  • Continuous Pharmaceutical Processes and Their Demands

    Continuous Pharmaceutical Processes and Their Demands

    Girish Malhotra, EPCOT International||April 5, 2016
    A look at the unique characteristics of continuous processes in pharmaceutical manufacturing.